Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy

作者：Taras Jillian; Arbess Gordon; Owen James; Guiang Charlie B; Tan Darrell H S^*

来源：Patient Preference and Adherence, 2014, 8: 1311-1316.

DOI：10.2147/PPA.S67090

• HIV
• bone antiresorptive therapy
• prophylaxis

Purpose: Both HIV infection and antiretroviral therapy (ART) are associated with significant decreases in bone mineral density (BMD) and increased fracture rates. To prepare for a randomized controlled trial of prophylactic bone antiresorptive therapy during ART initiation, we assessed the acceptability of this strategy, bone health knowledge, and fracture risk among HIV-infected adults.
Methods: HIV-infected adults with no history of osteoporosis were recruited from one tertiary and one primary care HIV clinic. Participants completed a questionnaire and underwent chart review. The primary outcome was the proportion of respondents expressing interest in taking prophylactic bone antiresorptive therapy in conjunction with ART.
Results: Of 112 respondents, 25.0% were ART naive, 23.2% had been taking ART for <= 1 year, and 51.8% had been taking ART for. 1 year. Half (51.9%) indicated interest in taking short-course prophylactic bone antiresorptive therapy; this did not differ by ART status (53.6% among ART-naive, 51.3% among ART-treated; P=0.84, chi-square test). In exploratory multivariable analysis adjusted for ART status, a greater number of pills taken per day was positively associated with this outcome (adjusted odds ratio [OR] = 1.12 per pill, 95% confidence limit [CL] = 1.01, 1.25), while male sex was inversely associated (adjusted OR = 0.05, 95% CL = 0.01, 0.24). Among those willing to take therapy, most (80.4%) were willing to do so for "as long as needed" and preferred weekly dosing (70.9%) to daily dosing (12.7%).
Conclusions: Half of this sample would be willing to take bone antiresorptive therapy together with ART, with preferences for weekly dosing and for whatever duration may be required. These data will inform the design of future trials to protect bone health in HIV.

• 出版日期2014